Novo Nordisk stock prices drop after Biden lists Ozempic for price negotiations
Stock prices for Novo Nordisk fell by about 3% at market open after the Biden administration selected its revolutionary drugs ...
Could Donald Trump Make Eli Lilly Stock a No-Brainer Buy in 2025?
Eli Lilly (LLY 1.45%) began a roll in late 2020 that lasted almost four years. During that time, it became the world's ...
Novo Nordisk’s Strategic Acquisition of Catalent: Short-term Challenges but Long-term Growth Potential with a Buy Recommendation
TD Cowen analyst Michael Nedelcovych has maintained their bullish stance on NVO stock, giving a Buy rating on January 13.Stay Ahead of the ...
Novo Nordisk drops after Ozempic selected for U.S. price negotiations
The stock is down 3%, or $2.81, to $80.26 in premarket trading.Stay Ahead of the Market:Discover outperforming stocks and invest smarter with ...
How Trump’s Greenland demands could impact Ozempic costs
President-elect Trump’s threat to tariff Denmark if it resists his acquisition plans for the island territory of Greenland ...
Lilly shares on track for worst day since 2021 after downbeat Zepbound sales forecast
Eli Lilly's stock tumbled 8% on Tuesday after it forecast fourth-quarter sales of weight-loss drug Zepbound below Wall Street ...
Trump’s plan to impose tariffs in bid to acquire Greenland could raise prices of Ozempic, Legos
President-elect Donald Trump’s threat to slap Denmark with tariffs to force its hand in giving up Greenland could lead to ...
Novo Nordisk's dosing in CagriSema obesity drug trial puzzles investors
Novo Nordisk shareholders were seeking on Friday to find out why such a high number of patients in the late-stage trial of its next-generation obesity drug candidate CagriSema did not reach the ...
Trump’s play for Greenland could make Ozempic more expensive
Denmark is the latest in a series of countries that President-elect Donald Trump has threatened with tariffs — joining a list ...
Hosted on MSN3d
Why Trump’s Denmark tariff would send the price of drugs like Ozempic through the roof
President-elect Donald Trump has not backed down from insisting that the United States needs to acquire Greenland, a Danish ...
Yahoo28d
An experimental drug drove people to lose 23% of their body weight. It’s still seen as a disappointment
Novo Nordisk CEO Lars Fruergaard Joergensen in December during a presentation of a new production site. The company's latest attempt at a weight loss drug, CagriSema, matched the bar set by a ...
AOL28d
Novo Nordisk stock sees biggest loss in more than 20 years on CagriSema results
Novo Nordisk (NVO) reported its newest GLP-1 product, CagriSema, provides an average of 22.7% weight loss, but that wasn't enough to convince investors, sparking a sell-off of the stock.